Moderate- to high-intensity statins for secondary prevention in patients with type 2 diabetes mellitus on dialysis after acute myocardial infarction

Table 2 Event numbers and hazard ratio of the primary outcome between the study cohorts

Outcome	Number of event (%)		Statin vs. non-statin
Outcome	Statin (n = 441)	Non-statin (n = 441)	HR (95% CI)	P value
3 Month follow-up
Non-fatal ischemic stroke	2 (.5)	5 (1.1)	.40 (.08, 2.05)	.271
Non-fatal myocardial infarction	13 (2.9)	12 (2.7)	1.09 (.50, 2.38)	.834
Cardiovascular death	13 (2.9)	21 (4.8)	.62 (.31, 1.24)	.173
Primary composite outcome^a	27 (6.1)	37 (8.4)	.73 (.44, 1.20)	.211
6 Month follow-up
Non-fatal ischemic stroke	6 (1.4)	8 (1.8)	.73 (.25, 2.10)	.559
Non-fatal myocardial infarction	26 (5.9)	24 (5.4)	1.06 (.61, 1.85)	.835
Cardiovascular death	24 (5.4)	27 (6.1)	.87 (.51, 1.52)	.633
Primary composite outcome^a	52 (11.8)	56 (12.7)	.91 (.62, 1.32)	.610
1 year follow-up
Non-fatal ischemic stroke	10 (2.3)	16 (3.6)	.58 (.26, 1.27)	.170
Non-fatal myocardial infarction	40 (9.1)	33 (7.5)	1.16 (.73, 1.83)	.541
Cardiovascular death	33 (7.5)	37 (8.4)	.85 (.53, 1.36)	.506
Primary composite outcome^a	77 (17.5)	78 (17.7)	.93 (.68, 1.28)	.660
At the end of follow-up
Non-fatal ischemic stroke	26 (5.9)	33 (7.5)	.58 (.35, .98)	.040
Non-fatal myocardial infarction	69 (15.6)	45 (10.2)	1.32 (.91, 1.92)	.149
Cardiovascular death	63 (14.3)	51 (11.6)	1.00 (.69, 1.45)	.982
Primary composite outcome^a	133 (30.2)	111 (25.2)	.98 (.76, 1.27)	.883

CI confidence interval, HR hazard ratio
^aAnyone of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke

ISSN: 1758-5996